Our Origins

Imperial College Bioincubator in London

TopiVert Pharma Limited (TopiVert) is a private UK company located at the Imperial College in London. The company was founded in 2011 to apply Non-Systemic Kinase Inhibitor (NSKI) technology in the fields of gastrointestinal (GI) diseases and ophthalmology (eye diseases). TopiVert was spun out of Respivert Ltd, a venture capital backed company acquired in 2010 by Centocor Ortho Biotech Inc. (now Janssen Biotech Inc., part of J&J), with a license to develop and commercialise NSKI based products in our chosen fields. Our investors include IP group (formerly Touchstone Innovations), SV Health Investors LLP and NeoMed alongside a strategic investment made by Johnson and Johnson Development Corporation (JJDC).

TopiVert has adopted a semi-virtual business model, using a combination of in-house expertise and a strong network of advisers and service providers, to expedite our programmes and achieve capital efficiency. Our high quality team is dedicated to our mission and we are passionate about our science.